BAZEDOXIFENE

Course overview

BAZEDOXIFENE, A SELECTIVE ESTROGEN RECEPTOR MODULATOR, IS PRIMARILY USED FOR THE MANAGEMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN. OSTEOPOROSIS IS CHARACTERIZED BY THE PROGRESSIVE DEGENERATION OF OVERALL BONE DENSITY, RENDERING THE PATIENT INCREASINGLY SUSCEPTIBLE TO PROXIMAL FRACTURES. BAZEDOXIFENE IS APPROVED BY THE U.S. FOOD AND DRUG ASSOCIATION (FDA) AS A COMBINATION DRUG USED IN CONJUNCTION WITH CONJUGATED ESTROGENS FOR MANAGING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE AND PREVENTING POSTMENOPAUSAL OSTEOPOROSIS. AS A COMBINATION DRUG, THIS MEDICATION HELPS PREVENT FRACTURES CAUSED BY OSTEOPOROSIS IN HIGH-RISK WOMEN WHO MAY HAVE CONTRAINDICATIONS TO OTHER CONVENTIONAL THERAPIES. THIS ACTIVITY REVIEWS THE INDICATIONS, MECHANISMS OF ACTION, ADMINISTRATION, POTENTIAL ADVERSE EVENTS, AND CONTRAINDICATIONS OF BAZEDOXIFENE. THIS ACTIVITY ALSO PROVIDES HEALTHCARE PROFESSIONALS WITH THE REQUISITE KNOWLEDGE AND TOOLS TO DELIVER OPTIMAL CARE FOR PATIENTS DEALING WITH OSTEOPOROSIS AND ASSOCIATED MENOPAUSAL SYMPTOMS THROUGH THE USE OF BAZEDOXIFENE.